Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors from the central anxious system, conolidine modulates alternate molecular targets. A Science Advances review identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://paxtonsadff.dailyblogzz.com/38374470/the-ultimate-guide-to-alternative-natural-pain-relief-to-replace-traditional-painkillers